Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical Sciences, Kitasato University, 3Department of Interna...
Guardado en:
Autores principales: | Abe S, Inoue G, Yamada S, Irie J, Nojima H, Tsuyusaki K, Usui K, Atsuda K, Yamanouchi T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/78ab0254b54545f09cc7a8c044ad71cb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
por: Natalya Nikitichna Volevodz, et al.
Publicado: (2013) -
Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson SE
Publicado: (2011) -
On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009) -
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau IT, et al.
Publicado: (2017) -
Lantus (Insulin Glargin): new insulin on Russian market
por: Editorial team Diabetes Mellitus
Publicado: (2003)